Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02312401 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

A Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
120
Enrollment target
8
Study locations

NCT02312401: Active Phase 2 study of Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02312401 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02312401, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to better understand prostate cancer changes after radiation treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows doctors to see prostate gland without any operation procedures. It can help identifying the tumors in the prostate. For patients with newly diagnosed prostate cancer, MRI may help doctors manage treatment better and sooner.

Primary Outcome

This change will then be correlated with the biopsy outcome (binary) by two sample t-tests.

Conditions Studied

Interventions

  • PROCEDURE biopsy
  • DEVICE multi-parametric MRI(MP-MRI)
  • DEVICE dynamic contrast-enhanced MRI (DCE)

Study Locations (8)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Rockville Centre - Rockville Centre
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2014-12
Est. Completion 2026-12
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT02312401 still lists

NCT02312401 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.

NCT02312401 lists 8 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT02312401 about?

NCT02312401 is a clinical study titled "Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy". The purpose of this study is to better understand prostate cancer changes after radiation treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows doctors to see prostate gland without any operation procedures. It can help identifying the tumors in the prostate. For pa...

What is the current status of trial NCT02312401?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2014-12. Estimated completion is 2026-12.

What conditions does trial NCT02312401 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02312401?

The interventions under investigation include: biopsy (PROCEDURE), multi-parametric MRI(MP-MRI) (DEVICE), dynamic contrast-enhanced MRI (DCE) (DEVICE).

Who is sponsoring clinical trial NCT02312401?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02312401 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02312401's enrollment target sits among peer trials

120 301st of 735 higher than 427 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02312401, the US trial registry maintained by the National Library of Medicine. NCT02312401 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.